![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » SAVIENT PHARMACEUTICALS, INC. COMPLETES SALE OF ROSEMONT PHARMACEUTICALS LTD. SUBSIDIARY FOR $176 MILLION
SAVIENT PHARMACEUTICALS, INC. COMPLETES SALE OF ROSEMONT PHARMACEUTICALS LTD. SUBSIDIARY FOR $176 MILLION
August 7, 2006
Savient Pharmaceuticals, Inc., a specialty pharmaceutical company engaged in developing, manufacturing, and marketing pharmaceutical products that address unmet medical needs, announced that it has completed the sale of its wholly-owned subsidiary, Rosemont Pharmaceuticals Ltd, to an entity affiliated with Close Brothers Private Equity for $176 million. Rosemont is a leading developer, manufacturer
and marketer of high quality oral liquid medicines in the United Kingdom.
BioSpace
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
21Oct